Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study

Authors:

Abstract
No abstract available
Funding Information
  • Bristol-Myers Squibb Co Summit
  • Bristol-Myers Squibb

This publication has 34 references indexed in Scilit: